A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC

This is a randomized, open-label, multicenter Phase Ib/II registration trial designed to evaluate the efficacy and safety of HH-009 in patients with FGF19-positive hepatocellular carcinoma (HCC). The study will also assess pharmacokinetics, pharmacodynamics, immunogenicity, and exploratory biomarkers. Approximately 30 patients with FGF19-positive advanced HCC will be enrolled. Eligible participants will be randomized 1:1 to receive HH-009 at either 20 mg/kg or 30 mg/kg Q3W as monotherapy. Treatment will continue until disease progression, unacceptable toxicity, initiation of new anticancer th

Trial Details

NCT ID
NCT07547553
Phase
PHASE1 / PHASE2
Sponsor
Huahui Health
Status
RECRUITING
Cancer Type
Liver Cancer
Interventions
  • Will receive HH-009 injection 20 mg/kg, Q3W
  • Will receive HH-009 injection 30 mg/kg, Q3W
Locations (sample)
  • Bengbu, Anhui, China|32.94083,117.36083
  • Hefei, Anhui, China|31.86389,117.28083
  • Hefei, Anhui, China|31.86389,117.28083
  • Beijing, Beijing Municipality, China|39.9075,116.39723
  • Beijing, Beijing Municipality, China|39.9075,116.39723

Key Eligibility Criteria

  • Voluntary participation in a clinical trial and signed informed consent.
  • Ages 18 to 75 years (inclusive of the boundaries), male or female.
  • Participants with advanced or unresectable HCC confirmed by pathological histology or diagnosed in accordance with the clinical criteria specified …
  • Participants with HCC who have experienced progressive disease after prio systemic therapy;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →